Highest-materiality recent filing
Guardant Health Q1 revenue rises 48% to $301.7 million, boosts 2026 guidance
Revenue increased 48% to $301.7M driven by Oncology revenue growth of 36% and Screening revenue surge to $41.6M.
Guardant Health Q4 revenue $281.3M (+39% YoY); 2026 revenue guided $1.25-1.28B
Q4 total revenue $281.3M (+39% YoY); Oncology tests 79k (+38%), Screening tests 38k.
Guardant Health reports Q4 revenue $280M (+39% YoY); full year revenue $981M (+33%)
Q4 oncology tests ~79,000 (+38% YoY); full year ~276,000 (+34%).
Guardant Health raises ~$717M via upsized equity and convertible debt offerings
Public offering of 3,833,332 shares at $90/share (incl. underwriter option), net proceeds ~$327.2M.
Guardant Health Q3 revenue $265.2M (+39% YoY); raises FY2025 revenue guidance to $965-$970M
Q3 total revenue $265.2M (+39% YoY); GAAP net loss $92.7M ($0.74/share), non-GAAP net loss $48.3M ($0.39/share).
Guardant Health Q2 revenue $232.1M (+31% YoY); raises FY2025 guidance to $915-925M
Q2 total revenue $232.1M (+31% YoY); Oncology $158.7M (+22%), Screening $14.8M, Biopharma $56.0M (+28%).
Guardant Health Q1 revenue $203.5M (+21% YoY); raises FY2025 revenue guidance to $880-$890M
Q1 total revenue $203.5M, +21% YoY; oncology $150.6M (+20%, 59K tests); screening $5.7M (9K Shield tests); biopharma $45.4M (+21%).
Full-year 2024 revenue $739M (+31% YoY); net loss $436.4M ($3.56 loss per share); non-GAAP net loss $247.2M ($2.01 loss per share).
Guardant Health issues $600M 1.25% convertible notes due 2031; retires $659.3M of 0% notes due 2027
Exchanged $600M new 1.25% convertible notes due 2031 for $659.3M of existing 0% notes due 2027.
Guardant Health exchanges $659.3M of 0% 2027 notes for $600M of 1.25% 2031 notes; plans $45M buyback
Issues $600M of 1.25% Convertible Senior Notes due Feb 15, 2031, exchanging for $659.3M of 0% Convertible 2027 Notes.
Guardant Health reports preliminary Q4 revenue ~$200M (+29% YoY); FY24 revenue $737M (+31%)
Total revenue Q4 ~$200M (+29% YoY); full year ~$737M (+31% YoY).
Guardant Health Q3 revenue $191.5M (+34% YoY); raises FY 2024 revenue guidance to $720-725M
Revenue $191.5M (+34% YoY); GAAP net loss $107.8M ($0.88/shr), Non-GAAP net loss $55.0M ($0.45/shr).
Guardant Health enters ATM sales agreement with Jefferies for up to $400M equity offering
Entered Open Market Sale Agreement with Jefferies LLC for at-the-market offering of common stock.
Guardant Health Q2 revenue up 29% to $177.2M, raises FY2024 guidance; FDA approves Shield CRC test
Revenue $177.2M (+29% YoY); precision oncology revenue $166.5M (+33%).
Guardant Health's Shield blood test gets FDA approval for colorectal cancer screening in ages 45+
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer.
FDA advisory panel strongly recommends approval of Guardant's Shield blood test for CRC screening
FDA advisory panel voted 8-1 that Shield is safe, 6-3 that it is effective, and 7-2 that benefits outweigh risks.
Guardant Health Q1 revenue up 31% to $168.5M; raises 2024 revenue guidance to $675-685M
Revenue $168.5M (+31% YoY); net loss narrowed to $115M ($0.94 loss per share) from $133.5M.
Fourth quarter 2023 revenue $155.1M, up 22% YoY; full year revenue $563.9M, up 25%.
Guardant Health reports preliminary 2023 revenue ~$562-563M (+25% YoY); clinical test volumes up 39%
Full year 2023 revenue $562-563M, up 25% YoY; clinical test volume 172,900 (+39%).
Guardant Health raises $90.7M in registered direct offering with Baillie Gifford
Raised ~$90.7M gross via 3,387,446 shares sold at $26.77 each to Baillie Gifford-managed accounts.
FDA's Molecular and Clinical Genetics Panel tentatively set to review Shield PMA on March 28, 2024, subject to confirmation.
Guardant Health hit with $83.4M patent infringement verdict; will appeal
Jury found willful infringement of two patents; awarded $83.4M in damages (6% royalty on past sales).
Guardant Health Q3 revenue $143M (+22% YoY); raises FY 2023 guidance to $553-556M
GAAP net loss $86.1M ($0.73/share) vs $162M ($1.58) YoY; non-GAAP loss $79.2M ($0.67).
Guardant Health COO Ines Dahne-Steuber resigns effective Nov 10, 2023
Ines Dahne-Steuber resigns as COO, effective November 10, 2023.
Guardant Health Q2 revenue $137.2M (+26% YoY); raises FY2023 revenue guidance to $545-550M
Revenue $137.2M (+26% YoY); clinical test volume 43,500 (+49%), biopharma tests 6,700 (+12%).
Guardant settles Illumina litigation, extends commercial partnership with three-year agreement
Guardant and Illumina agreed to dismiss with prejudice the March 2022 Delaware lawsuit, including all IP allegations.
Guardant Health closes $380.5M equity offering of 14.375M shares at $28.00
Issued 14.375M shares including full exercise of underwriters' option for net proceeds ~$380.5M.
Guardant Health reports Shield test 83% sensitivity, 90% specificity for CRC in ECLIPSE study at DDW
Shield blood test achieved 83% overall sensitivity and 90% specificity in detecting colorectal cancer in average-risk adults.
Guardant Health Q1 revenue up 34% to $128.7M; raises FY2023 guidance to $535-545M
Revenue $128.7M (+34% YoY); clinical tests 39,100 (+45%), biopharma tests 6,150 (+21%).
Guardant Health confirms no deposits or investments at Silicon Valley Bank
Aware of FDIC takeover of SVB due to liquidity concerns.
Guardant Health Q4 revenue $126.9M (+17% YoY); net loss widens to $139.9M; guides FY23 rev $525-540M
Q4 revenue $126.9M (+17% YoY); full-year revenue $449.5M (+20% YoY).
Guardant Health prelim FY22 revenue $447-450M, up 20%; test volumes up >40% YoY
Preliminary FY22 revenue $447M-$450M, up 20% YoY; Q4 revenue $124M-$127M, up 15-17%.
ECLIPSE study: 83% sensitivity for CRC detection, 90% specificity vs. negative colonoscopy.
On October 21, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Roberto Mignone., as a Class I director of the Company, to be effective as of October 21, 2024.
On July 17, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Manuel Hidalgo Medina, M.D., Ph.D., as a Class II director of the Company, to be effective as of July 17, 2024.
On January 26, 2024, Mr. Samir Kaul notified the board of directors (the “Board”) of Guardant Health, Inc. (the “Company”) that he intends to resign as member of the Board and as a member of the compensation committee of the Board effective February 1, 2024.
On November 2, 2023, Ms. Ines Dahne-Steuber tendered her resignation as Chief Operating Officer of Guardant Health, Inc., effective as of November 10, 2023.
On May 3, 2023, the Board of Directors (the “Board”) of the Guardant Health, Inc. (the “Company”) appointed Ines Dahne-Steuber to serve as the Company’s Chief Operations Officer, effective May 3, 2023.
appointed Musa Tariq as a Class I director of the Company, to be effective as of March 6, 2023.
Effective June 30, 2022, the Board of Directors (the “ Board ”) of Guardant Health, Inc. (the “ Company ”) increased the number of directors on the Board to eight and appointed Steve E. Krognes as a Class III director of the Company.
On May 4, 2022, Dr. Bahija Jallal notified the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) of her decision to resign as a director of the Company, effective as of the Company’s next Annual Meeting of Stockholders, which will take place on June 15, 2022.
On February 22, 2022, Stanley Meresman informed Guardant Health, Inc. (the “Company”) that he will not stand for re-election to the Company’s Board of Directors (the “Board”) when his current term expires at the Company’s next Annual Meeting of Stockholders, which will take place in June 2022.
Effective October 15, 2021, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Myrtle Potter as a Class I director of the Company.
the Board increased the number of directors on the Board to eight and appointed Meghan Joyce as a Class II director
changed the title of Helmy Eltoukhy, the Company’s current Chief Executive Officer, to the Company’s Co-CEO
Max materiality 0.90 · Median 0.70 · Most common event earnings